← Voyager Acquisition Corp./Cayman Islands (VACH) — catalysts, pipeline & price
Catalyst Dossier · compiled by CeliA 🧫
Voyager Acquisition Corp./Cayman Islands (VACH)
Biological Products, (No Diagnostic Substances) · market cap $256M · as of 2026-07-11
Research and calibrated estimates, not financial advice — verify before acting.
Next catalyst
2027-05-15 (est.)
Phase 2
Pipeline
3
programs
Upcoming events
1
next 90d+
Dossier
Ready
cached
Voyager Acquisition Corp. (VACH) is a Cayman Islands-incorporated entity in the biological products sector with a market cap of approximately $433M at ~$17.11/share. Its pipeline is focused entirely on Alzheimer's Disease, with VP4896 in Phase 3, leuprolide acetate in Phase 2, and VY7523 in Phase 2. Financial disclosures show effectively zero cash and a runway of roughly 0.1 months, raising immediate going-concern questions.
The catalyst path
- 2027-05-15 (est.)Phase 2 · VY7523imp 7/10
Pipeline
| Asset | Phase | Indication |
|---|---|---|
| Leuprolide acetate | Phase 2 | Alzheimer Disease |
| VP4896 | Phase 3 | Alzheimer's Disease |
| VY7523 | Phase 2 | Alzheimer's Disease (AD) |
Price & technical context
3-month
-4.4%
6-month
-3.2%
12-month
-1.0%
52-wk range
$10.10–$12.48
vs 50-day MA
-6.2%
vs 200-day MA
-4.2%
Realized vol
25.0%
Max drawdown
-19.1%
Daily closes through 2026-03-23. Realized vol annualized; max drawdown over ~2 years.
The full dossier is a Pro feature
Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.
Sources & data
- SEC filings — EDGAR filings for VACH (10-K, 10-Q, S-3, 13D/G, Form 4)
- Clinical trials — 3 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
- Market & financial data — SEC EDGAR (XBRL filings, Form 4), Yahoo Finance, Nasdaq — prices, statements, key metrics, insider & institutional filings.
- Regulatory — openFDA, FDA advisory & PDUFA calendars.
Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.
Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, market-data providers). Compiled by CeliA. Not financial advice.